penicillamine has been researched along with 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Antonini, A; Kirsch, CM; Kraft, E; Leenders, KL; Oertel, WH; Schwarz, J; Tatsch, K; Vogl, T | 1 |
1 other study(ies) available for penicillamine and 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide
Article | Year |
---|---|
Treatment with D-penicillamine improves dopamine D2-receptor binding and T2-signal intensity in de novo Wilson's disease.
Topics: Adolescent; Adult; Benzamides; Brain; Hepatolenticular Degeneration; Humans; Magnetic Resonance Imaging; Male; Penicillamine; Pyrrolidines; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon | 1994 |